

Supplementary Table S2. Classification scheme developed for the molecular tumor boards of the National Center for Tumor Diseases (NCT) and the German Cancer Consortium (DKTK) (Leichsenring et al. 2019).

Same entity	M1A	Predictive value of the biomarker or clinical effectiveness of the corresponding drug in a molecularly stratified cohort was demonstrated in a prospective study or a meta-analysis in the same tumor type.
	M1B	Predictive value of the biomarker or clinical effectiveness of the drug in a molecularly stratified cohort was demonstrated in a retrospective cohort or case-control study in the same tumor type.
	M1C	Case study or single unusual responder indicates the biomarker is associated with response to the drug in the same tumor type.
Different entity	M2A	Predictive value of the biomarker or clinical effectiveness of the corresponding drug in a molecularly stratified cohort was demonstrated in a prospective study or a meta-analysis in a different tumor type.
	M2B	Predictive value of the biomarker or clinical effectiveness of the drug in a molecularly stratified cohort was demonstrated in a retrospective cohort or case-control study in a different tumor type.
	M2C	Case study or single unusual responder indicates the biomarker is associated with response to the drug in a different tumor type.
Preclinical	M3	Preclinical data (in vitro, in vivo models or functional genomics studies) demonstrate that the biomarker predicts response to a specific drug treatment, supported by scientific rationale.
Biological rationale	M4	Biological rationale that associates the biomarker with altered signaling pathway activity or drug sensitivity without direct clinical or preclinical evidence for response to the drug.
Additional Modifiers:		
<i>is</i>	several in situ data and studies on patient material (e.g. IHC, FISH) support the biomarker and the level of evidence.	
<i>iv</i>	in vitro data	
<i>Z</i>	Drug is approved for use with the specific biomarker (Z= EMA approval, Z(FDA)=FDA approval)	
<i>R</i>	Biomarker predicts resistance to the drug.	

Bibliography

- (1) Leichsenring J, Horak P, Kreutzfeldt S, et al (2019) Variant classification in precision oncology. Int J Cancer 145:2996–3010. <https://doi.org/10.1002/ijc.32358>

Molecular Tumor Board in Advanced Sarcoma: Treatment Implementation and Clinical Outcomes in a Real-World Cohort

Journal of Cancer Research and Clinical Oncology

Christoph Weinfurter et al.

Corresponding author: Verena I. Gaidzik, Department of Internal Medicine III, University Hospital Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany. Email: verena.gaidzik@uniklinik-ulm.de